Key facts
as of Sep 2026- Kartos Therapeutics’s last known valuation is $650.0M (Aug 2023).
- It has raised $265.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include OrbiMed, SR One Capital Management, Amgen, Quogue Capital.
- 1 institutional filer reports fund marks on Kartos Therapeutics across 6 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Kartos Therapeutics
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Kartos Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
1 filers · latest Apr 20261 SEC-registered fund reported 6 fair-value marks on Kartos Therapeutics between Apr 2025 and Apr 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Kartos Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Kartos Therapeutics
Operator of a biopharmaceutical company intended to offer investigational inhibitors for cancer treatment. The company specializes in the development of novel, targeted therapeutics and provides a new treatment option for patients across selected solid tumors and hematological malignancies, enabling cancer patients to improve their lives.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2018
- Employees
- 87
- Website
- kartosthera.com/
- Ownership
- Privately Held (backing)